A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. - Wikidata - awgldk - TriplyDB

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.

http://www.wikidata.org/entity/Q34599344

about

Targeted therapy of gastrointestinal stromal tumours Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.Current management and prognostic features for gastrointestinal stromal tumor (GIST)Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies Gastrointestinal stromal tumor and its targeted therapeutics.Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors Targeted therapy for cancer: the gastrointestinal stromal tumor model.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy.Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).Updates on the management of gastrointestinal stromal tumors.Adjuvant treatment of GIST: patient selection and treatment strategies.Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.A gist of gastrointestinal stromal tumors: A review.Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors.Diagnosis and evaluation of gastric cancer by positron emission tomography GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experience Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors.Gastrointestinal tumors of the colon and rectum Esophageal gastrointestinal stromal tumor: report of 7 patients Exploiting antitumor immunity to overcome relapse and improve remission duration.(18)F-FDG PET in sarcoma treatment response imaging.Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors Modern treatment of gastric gastrointestinal stromal tumors.Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors : recommendations for patient selection, risk assessment, and molecular response monitoring.BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib.Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors.Targeted therapy for sarcomas.Recent advances in the treatment of gastrointestinal stromal tumors.Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.Current and emerging pharmacological treatments for gastrointestinal stromal tumour.Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors.Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.

P2860

Q26745633-F45ACE02-D78A-4702-AF2E-EF087B240611 Q27027632-2B105F44-9970-4356-9479-277C3F26C3AC Q27851482-C149F1D7-E27B-416D-BA33-1C6642AAE551 Q28391684-0B0FEDB8-4477-4F45-8169-CC43185FB39B Q33572971-CEAB88EA-6B02-495E-94D2-2C440B64AD92 Q33579642-0983B955-82A7-462D-AA86-1D1BAB524A68 Q33777447-75611111-E974-4376-9579-540DAA96C9D6 Q33807742-8A3148AF-4CFD-4C4F-B98E-2BF12414C2D1 Q33921067-62C05362-6BF5-472E-8962-6A8FCEDB31E8 Q34029127-8441EE2A-E087-4F39-8EF6-979F2A302122 Q34050275-19C18765-8755-4CCE-8593-2D2239340F59 Q34069556-CC5A331D-8E63-4C6B-951A-DAC00D7B6FCE Q34256921-2BFC057A-D1D1-44A5-B9A7-B548A4C586FF Q34270274-D8E83AF6-C0E5-46E6-91EC-D24A41B41C4F Q34300784-E41D91AD-AE6C-4417-97D1-FA1A85CC736F Q34654203-30F74AAD-32B0-4B33-A374-86882C37BAB3 Q34660414-C5F9D00C-0485-4775-A3BE-99F62C30A73E Q34661633-25A5EEED-D6BE-4A2E-927D-FCE6A69E54DB Q34664305-23E89BAB-3277-49A1-9A0C-5B26F5CCFCA7 Q35572873-F5AAA230-2AE0-40F6-924F-A57AD24A3D0A Q35607790-8555A7A6-4AAA-44DD-A4FD-B4B12263D3B5 Q35850185-30987D1E-FFA2-4A75-AE8A-A3148FF71DC0 Q35996663-F14FB630-0C17-4FE8-8ECD-2EE1F11B1D0F Q36044604-054C219E-0DD0-4EEE-9A39-92EF16E93902 Q36337223-1F672C1A-66F4-48C6-8AEA-5AFB5C25AEF5 Q36447011-C223080D-4540-4141-9D0D-B51FE9631523 Q36460991-795B92FE-A1F0-4D20-ABA0-0EFAF0DA1158 Q36499861-3B5337EF-AD92-40E4-AC8D-7B6C35534C44 Q36589296-BA664C65-99E6-4FDA-94DC-406F2D1B8848 Q37016582-C7084D13-2138-4BE9-AE5A-AF203C9AA9B1 Q37131713-23DEC0EF-971D-4586-A859-88A31DDF2EF5 Q37238580-59153817-7B35-4187-A9B8-579D5EB056DA Q37298437-ED2F8C49-8B61-49A2-9ACA-6C2A57C40456 Q37655450-3956D5AF-413E-4A23-9054-77CBBAD1B0DC Q37704347-97202F00-8989-4E40-8861-765B59F83A91 Q37823438-3AB6F867-A10C-49F7-A446-13C4F4D5CAFD Q37841551-03E3C115-2714-434B-9464-4C98477C8C28 Q37889247-8B09AADE-7E9E-4427-9B10-86F2402C5A59 Q37954205-E002D781-EDA7-4CB7-A81E-1ED5FE464591 Q38030856-D7E32CA6-DA67-4AD6-B2C8-9D40DB694FC3

P2860

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.

http://www.wikidata.org/entity/Q34599344

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

A randomized, phase II study o ...... ction of tumor cell apoptosis.

@ast

A randomized, phase II study o ...... ction of tumor cell apoptosis.

@en

A randomized, phase II study o ...... ction of tumor cell apoptosis.

@nl

type

label

A randomized, phase II study o ...... ction of tumor cell apoptosis.

@ast

A randomized, phase II study o ...... ction of tumor cell apoptosis.

@en

A randomized, phase II study o ...... ction of tumor cell apoptosis.

@nl

prefLabel

A randomized, phase II study o ...... ction of tumor cell apoptosis.

@ast

A randomized, phase II study o ...... ction of tumor cell apoptosis.

@en

A randomized, phase II study o ...... ction of tumor cell apoptosis.

@nl

P1433

Q34599344-DA029FF8-5F78-4668-B182-69969BF13A63

P1476

Q34599344-B3A29CB5-A0F9-49AE-B183-43E0158957EF

P2093

Q34599344-46A982F8-227C-4159-89BA-FA723782A2C2

Q34599344-595D8D82-75E1-4539-9CBD-8979A933FFC3

Q34599344-69AAE028-63D8-4F54-A41F-02A49DAD7B58

Q34599344-8DDDCAC2-2B1A-4660-B41D-A672A0FF1BF7

Q34599344-A517284D-7E05-483D-BA4F-571AB3B2CB54

Q34599344-B5259795-017C-492B-9081-598F543E1606

Q34599344-BA441385-BC3D-460E-8A9E-B06F743A6AAB

Q34599344-D8FFB747-EB00-4849-9C5F-A7B424EF51EA

P2860

Q34599344-1850DBD8-DB10-40F1-921F-9BB2F4EF9DB2

Q34599344-1B756B8F-D595-4C1F-90D0-4165D43D25CA

Q34599344-1F2072CB-DA75-46B7-BF81-8A7D7A847EAE

Q34599344-20A1C2B5-E28D-4FBD-911B-6F7B7ED979E9

Q34599344-24AA089C-7232-45CF-BA10-7A8BF48E2042

Q34599344-2F6699B6-590C-43EB-8CBD-E892CA6A1C58

Q34599344-491F4018-6F4C-4C57-ABF7-78E811E1A3FA

Q34599344-5BAF558B-6CB0-4B8B-8566-F0BC4D2F686D

Q34599344-5FAAF06D-C7EC-4792-8062-6D2DDBD3179E

Q34599344-6800E33E-F35B-4FC7-83CF-43F84ADDE243

P2888

Q34599344-BD838734-42EB-44EF-B133-6F04C4F0C403

P304

Q34599344-15F1D639-54BF-4D68-A42D-B063558A559E

P31

Q34599344-1E088B84-7652-4FD7-A2A5-F16BCE8B27BB

P356

Q34599344-0CBEC9C7-7FA0-43A1-9F83-A813EE54E161

P433

Q34599344-BDDF63E2-6A9E-4653-B56C-3B7CA424D0D8

P478

Q34599344-BF1B3B33-846F-4548-B281-7FF6DB424A0A

P50

Q34599344-6E76954F-DFE5-4768-8A42-44990FAC33C7

P577

Q34599344-24C93D99-94B0-489E-B135-CDE0ADD154F1

P5875

Q34599344-AB19E37F-3480-4678-BE55-22A132F7E358

P6179

Q34599344-3AB016B1-2B15-4B7A-9FA4-973BA641387D

P698

Q34599344-B0A18E19-6487-4790-A048-974B1F9F968A

P932

Q34599344-4198FAE5-E6E0-4FC8-958F-12D403EDF2B7

P356

S10434-008-0177-7

P1433

Annals of Surgical Oncology

P1476

A randomized, phase II study o ...... ction of tumor cell apoptosis.

@en

P2093

Haesun Choi

http://www.w3.org/2001/XMLSchema#string

John C McAuliffe

http://www.w3.org/2001/XMLSchema#string

Jonathan C Trent

http://www.w3.org/2001/XMLSchema#string

Kelly K Hunt

http://www.w3.org/2001/XMLSchema#string

Peter Thall

http://www.w3.org/2001/XMLSchema#string

Raphael E Pollock

http://www.w3.org/2001/XMLSchema#string

Robert S Benjamin

http://www.w3.org/2001/XMLSchema#string

Wei Qiao

http://www.w3.org/2001/XMLSchema#string

P2860

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.

PDGFRA activating mutations in gastrointestinal stromal tumors.

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

P2888

s10434-008-0177-7

P304

910-919

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-008-0177-7

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Alexander J. Lazar

P577

2008-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23416849

http://www.w3.org/2001/XMLSchema#string

P6179

1020576126

http://www.w3.org/2001/XMLSchema#string

P698

18953611

http://www.w3.org/2001/XMLSchema#string

P932

5647649

http://www.w3.org/2001/XMLSchema#string